Genzyme, a Sanofi company with over 30 years of dedication to researching and developing novel treatments for rare and orphan diseases, has just announced the Alberta Drug Program has finally decided to include Aubagio® (teriflunomide) 14mg in the provincial drug formulary, indicated for the first-line treatment of patients with relapsing remitting multiple sclerosis (RRMS). Alberta, Canada has one of the highest rates of MS worldwide, with over 14,000 residents diagnosed with some form of this neurodegenerative, autoimmune disease. Now, more Albertans with MS can gain access to Aubagio, a novel, orally stable drug capable of reducing exacerbations and delaying the development of physical disabilities.
Aubagio was first approved in Canada in November of 2013. While the drug’s exact mechanism of action as an immunomodulator and anti-inflammatory is not known, it is thought to greatly reduce the amount of harmful lymphocytes that attack the protective myelin sheath. The drug has performed impressively in over 5,000 study participants across 36 countries, with patients in extension trials still benefitting from the treatment even 10 years later.
~~~~~~~~~~~~~~~~~~~~
.
.
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
